Gritstone Bio Price to Sales Ratio 2017-2022 | GRTS
Historical PS ratio values for Gritstone Bio (GRTS) over the last 10 years. The current P/S ratio for Gritstone Bio as of July 01, 2022 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Gritstone Bio P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2022-07-01 |
2.46 |
|
12.76 |
| 2022-03-31 |
4.12 |
$0.19 |
21.36 |
| 2021-12-31 |
12.86 |
$0.62 |
20.68 |
| 2021-09-30 |
10.80 |
$0.62 |
17.46 |
| 2021-06-30 |
9.13 |
$0.61 |
14.97 |
| 2021-03-31 |
9.43 |
$0.59 |
16.09 |
| 2020-12-31 |
3.94 |
$0.11 |
36.50 |
| 2020-09-30 |
2.65 |
$0.10 |
26.87 |
| 2020-06-30 |
6.64 |
$0.10 |
65.54 |
| 2020-03-31 |
5.82 |
$0.12 |
47.53 |
| 2019-12-31 |
8.97 |
$0.13 |
66.59 |
| 2019-09-30 |
8.64 |
$0.23 |
37.43 |
| 2019-06-30 |
11.14 |
$0.24 |
45.96 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.179B |
$0.048B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
